Advertisement

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

ACCEPT AND CLOSE

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

50% off your first year of ACS membership = 100% yield

Already an ACS Member?  

Membership categories

Choose the membership that is right for you. Discounts will be applied automatically at checkout.

Regular or Affiliate Member
$175
$88
JOIN NOW
Graduate Student Member
$87
$44
JOIN NOW
Undergraduate Student Member
$60
$30
JOIN NOW

Benefits

Enjoy these benefits no matter which membership you pick.

 

  • Unlimited access to C&EN, including a subscription to our award-winning weekly print magazine
  • Discounts on ACS meetings, events and courses
  • Expand your research with complimentary SciFinder searches
  • Discounts on ACS journals
  • Receive exclusive career insights and data from industry experts

Thank you!

Your account has been created successfully, and a confirmation email is on the way.

Your username is now your ACS ID.

ENJOY UNLIMITED ACCES TO C&EN
Untitled Document
 

_____ Brought to you by Bruker _____

Oligonucleotide Analysis Simplified!
MALDI and ESI Solutions

REGISTER NOW
 

  April 24, 2019

  8:00 a.m. PDT, 11:00 a.m. EDT, 16:00 BST, 17:00 CEST

 

Overview

 

There has been noteworthy progress in the oligonucleotide therapeutics field over the past 30 years, beginning with antisense oligonucleotides (ASOs) and aptamers and followed about 15 years ago by siRNAs. Recent innovations in gene editing field is driving the need for oligonucleotides characterization.

MALDI and ESI Mass Spectrometry have prominent roles to play in the life cycle of oligonucleotide drugs from discovery to QC for determination of the molecular weights of natural and synthetic oligonucleotides and in sequencing of DNA and RNA species. Both techniques also have their specific strengths and drawbacks. MALDI-TOF is relatively easy to operate, offers high sensitivity for oligonucleotides, and is well suited to a high-throughput environment. MALDI‐TOF is also reasonably tolerant to the presence of salts, buffers, and other additives. Alternatively, ESI technology maintains high mass accuracy, resolution, and sensitivity over a range of lengths (20–120 bases), but has a reduced throughput and requires more attention to sample cleanliness.

Bruker offers a complete solution for oligonucleotide screening and QC applications with a broad portfolio of innovative and best-in-class MALDI-TOF and UHR ESI-TOF instruments and an integrated software solution for both techniques.

BioPharma Compass 3.1 enables the routine analysis of biopharmaceuticals offering dedicated LC MS workflows including automated measurements and report generation. Both high resolution ESI-QTOF and MALDI-TOF data can be employed for these analyses. Similarity scores and mass accuracy attributes are the basis for an automatic pass/fail assessment. Reports utilize color coding of results and charts for rapid reviewing. Butterfly plots enable visual dataset comparisons.

Brought to you by:

 

Key Learning Objectives

  • Role of Oligonucleotides in drug discovery
  • Oligonucleotide analysis by MALDI and ESI UHR QTOF instruments
  • Biopharma Compass – an integrated software solution for both MALDI and ESI data

Who Should Attend

  • Scientists interested in screening and QC of oligonucleotide drugs
  • Scientists interested in MALDI and ESI analysis of oligonucleotides
 

Speaker

Anjali Alving,
Senior Applications Scientist,
Bruker Scientific
 

Moderator

Jeff Huber,
Contributing Editor,
C&EN Media Group
 

REGISTER NOW